Table 2.
Unadjusted comparisons for hospital admission within two weeks of COVID testing and for overall 30-day mortality *.
| Admitted (n = 1,040) |
Not Admitted (n = 1,553) |
P- value***** | Alive (n = 2,408) |
Deceased (n = 186) |
p-value***** | |
|---|---|---|---|---|---|---|
|
PPI usage** (n,%) |
Active use: 286 (27.5%) Past use: 54 (5.2%) No use: 700 (67.3%) |
Active use: 162 (10.4%) Past Use: 44 (2.8%) No use: 1,347 (86.7%) |
< .0001 |
Active use: 392 (16.3%) Past use: 87 (3.6%) No use: 1,929 (80.1%) |
Active use: 56 (30.1%) Past Use: 11 (5.9%) No use: 119 (64%) |
< .0001 |
|
Age, years (mean ± SD)** |
66.5 ± 17.2 | 43.4 ± 16.5 | < .0001 | 50.7 ± 19.4 | 77.7 ± 12.8 | < .0001 |
|
Gender (n,%) |
488 female (46.9%) 552 male (53.1%) |
820 female (52.8%) 733 male (47.2%) |
.003 |
1,229 female (51%) 1,179 male (49%) |
80 female (43%) 106 male (57%) |
.04 |
|
Race (n,%) |
677 white (65.1%) 363 non-white/other/did not answer (34.9%) |
817 white (52.6%) 736 non-white/other/did not answer (47.4%) |
< .0001 |
1,352 white (56.1%) 1,056 non-white/other/did not answer (43.9%) |
143 white (76.9%) 43 non-white/other/did not answer (23.1%) |
< .0001 |
|
BMI, kg/m2 (mean ± SD)** |
30.5 ± 8.4 | 30.9 ± 7.3 | .28 | 31.0 ± 8.1 | 28.3 ± 5.9 | < .0001 |
|
Diabetes (n,%) |
498 (47.9%) | 277 (14.6%) | < .0001 | 630 (26.2%) | 95 (51.1%) | < .0001 |
|
COPD** (n,%) |
227 (21.8%) | 39 (2.5%) | < .0001 | 201 (8.3%) | 65 (34.9%) | < .0001 |
|
Cardiovascular disease*** (n,%) |
448 (43.1%) | 109 (7%) | < .0001 | 445 (18.5%) | 113 (60.8%) | < .0001 |
|
Kidney disease (n,%) |
351 (33.8%) | 56 (3.6%) | < .0001 | 308 (12.8%) | 100 (53.8%) | < .0001 |
|
Cancer (n,%) |
177 (17%) | 70 (4.5%) | < .0001 | 190 (7.9%) | 57 (30.6%) | < .0001 |
|
Obesity**** (n,%) |
503 (48.4%) | 477 (30.7%) | < .0001 | 905 (37.6%) | 75 (40.3%) | .46 |
*Denominators differ for some variables due to missing data.
**PPI Proton pump inhibitor, SD Standard deviation, COPD Chronic obstructive pulmonary disease.
***Cardiovascular disease is a composite of cardiomyopathy, congestive heart failure, and coronary artery disease.
****Defined as BMI > 30 kg/m2.
*****Based on separate one-way analysis of variance or chi square tests, as appropriate.